Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Tappenden

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
JAMA Network Open|May 28, 2020
Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease ModelHuajie Jin, Paul Tappenden, James H MacCabe, et al.
International Journal of Technology Assessment in Health Care|July 8, 2008
Use of expert knowledge in evaluating costs and benefits of alternative service provisions: a case studyPaul H Garthwaite, James B Chilcott, David J Jenkinson, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2006
Methodological issues in the economic analysis of cancer treatmentsPaul Tappenden, Jim Chilcott, Sue Ward, et al.
Clinical Therapeutics|August 6, 2010
Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysisChristopher Carroll, Katy Cooper, Diana Papaioannou, et al.
Plos One|July 11, 2020
Systematic review of the methods of health economic models assessing antipsychotic medication for schizophreniaHuajie Jin, Paul Tappenden, Stewart Robinson, et al.
Gut|December 5, 2006
Option appraisal of population-based colorectal cancer screening programmes in EnglandPaul Tappenden, James Chilcott, Simon Eggington, et al.
Clinical Therapeutics|August 16, 2011
Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancerHazel Squires, Paul Tappenden, Katy Cooper, et al.
BMJ Open|November 6, 2013
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)John Rathbone, Eva Kaltenthaler, Anna Richards, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 26, 2013
Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single modelPaul Tappenden, Jim Chilcott, Alan Brennan, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 14, 2020
Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendationsHuajie Jin, Paul Tappenden, James H MacCabe, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
JAMA Network Open|May 28, 2020
Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease ModelHuajie Jin, Paul Tappenden, James H MacCabe, et al.
International Journal of Technology Assessment in Health Care|July 8, 2008
Use of expert knowledge in evaluating costs and benefits of alternative service provisions: a case studyPaul H Garthwaite, James B Chilcott, David J Jenkinson, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2006
Methodological issues in the economic analysis of cancer treatmentsPaul Tappenden, Jim Chilcott, Sue Ward, et al.
Clinical Therapeutics|August 6, 2010
Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysisChristopher Carroll, Katy Cooper, Diana Papaioannou, et al.
Plos One|July 11, 2020
Systematic review of the methods of health economic models assessing antipsychotic medication for schizophreniaHuajie Jin, Paul Tappenden, Stewart Robinson, et al.
Gut|December 5, 2006
Option appraisal of population-based colorectal cancer screening programmes in EnglandPaul Tappenden, James Chilcott, Simon Eggington, et al.
Clinical Therapeutics|August 16, 2011
Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancerHazel Squires, Paul Tappenden, Katy Cooper, et al.
BMJ Open|November 6, 2013
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)John Rathbone, Eva Kaltenthaler, Anna Richards, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 26, 2013
Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single modelPaul Tappenden, Jim Chilcott, Alan Brennan, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 14, 2020
Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendationsHuajie Jin, Paul Tappenden, James H MacCabe, et al.
Pageof 9